MicroRNA-200b expression level is negatively associated with pathological grading in human gliomas
Authors Kong X, Gong S, Yan T, Yang Y
Received 14 April 2018
Accepted for publication 18 June 2018
Published 24 August 2018 Volume 2018:10 Pages 2825—2834
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 4
Editor who approved publication: Dr Antonella D'Anneo
Xiangyi Kong,1,2,* Shun Gong,3–5,* Tao Yan,6,* Yi Yang1
1Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, People’s Republic of China; 2Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China; 3Department of Neurosurgery, The General Hospital of Shenyang Military, Army Institute of Neurology, Shenyang 110016, People’s Republic of China; 4Department of Neurosurgery, Shanghai Institute of Neurosurgery, PLA Institute of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People’s Republic of China; 5Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 6Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China
*These authors contributed equally to this work
Aim: To elucidate the clinical implication of microRNA (miRNA)-200b in the pathological grading of gliomas.
Methods: We searched the Chinese National Knowledge Infrastructure, Web of Knowledge, Embase, and PubMed databases. Related articles were assessed, and ORs with 95% CIs were calculated to examine the relationship between miRNA-200b expression levels and the World Health Organization (WHO) glioma grade, patients’ sex and age, tumor size, and extent of surgical resection. Heterogeneity, publication bias, and stability of the pooled results of the included studies were also analyzed. MiR-200b expression in 87 human glioma tissues (50 high grade and 37 low grade) and matched 41 non-neoplastic brain tissues was measured by real-time quantitative RT-PCR assay.
Results: Five eligible studies involving 630 patients were included in the present meta-analysis. The miRNA-200b expression in glioma tissues was negatively associated with the WHO glioma grade (OR, 0.070; 95% CI, 0.007–0.678; P=0.022). No significant correlations were found between miRNA-200b and sex (P=0.858), age (P=0.776), tumor size (P=0.134), or extent of resection (P=0.778). In our own test, compared with non-neoplastic brain tissues, the expression level of miR-200b was significantly decreased in glioma tissues (tumor vs normal: 4.29±1.90 vs 10.45±2.34, P<0.001). In addition, we found that the glioma tissues from high-grade tumors (grade III and IV) had much lower miR-200b expression than glioma tissues from low grade tumors (grade I and II).
Conclusion: Our results suggest that the miRNA-200 expression level may be negatively associated with the WHO glioma grade (malignancy). MiRNA-200 might serve as a prognostic and diagnostic biomarker or a helpful therapeutic target.
Keywords: microRNA-200b, down-regulation, glioma, grade, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]